STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2022

Dec 22, 2022

==> picture [136 x 45] intentionally omitted <==

December 22, 2022

BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR

Dear Sirs,

Sub: Receipt of AUD 94 million on account of deferred consideration on the sale of the Company’s Australian operations in 2019

We would like to inform you that Strides Pharma Global Pte Limited, a step-down subsidiary of the Company in Singapore, has received AUD 94 Million as the deferred consideration for the sale of the Company’s Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet.

Strides, in 2019, exited its investments in Australia for AUD 394 million. The company received AUD 300 million immediately on the transaction's closing, and the same was used towards significant deleveraging of the balance sheet through repayment of debt. The balance of AUD 94 Million was a deferred consideration backed by a secured interest-bearing instrument.

Strides continues to be a preferred supplier to Arrotex, which is the largest generic company in Australia.

We request that you take the above on record.

Thanks & Regards,

For Strides Pharma Science Limited,

MANJULA Digitally signed by MANJULA RAMAMURTHY RAMAMURTHY Date: 2022.12.22 11:01:03 +05'30' Manjula Ramamurthy Company Secretary

==> picture [479 x 52] intentionally omitted <==